References

Systemic light chain amyloidosis

10.1056/nejmra2304088 · 2024 · External reference

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

10.1200/jco.2011.38.5724 · 2012 · External reference

What is new in diagnosis and management of light chain amyloidosis?

10.1182/blood-2016-01-629790 · 2016 · External reference

Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment

10.1002/ajh.27177 · 2024 · External reference

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

10.1182/blood-2015-01-620302 · 2015 · External reference

Daratumumab-based treatment for immunoglobulin light-chain amyloidosis

10.1056/nejmoa2028631 · 2021 · External reference

Subcutaneous daratumumab (DARA) + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: overall survival and final major organ deterioration progression-free survival results from the phase 3 ANDROMEDA study

10.1182/blood-2024-205077 · 2024 · External reference

Targeting B cell maturation antigen in patients with multiple myeloma: current perspectives

10.2147/ott.s370880 · 2023 · External reference

Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies

10.1016/j.ymthe.2024.05.039 · 2024 · External reference

Idecabtagene vicleucel in relapsed and refractory multiple myeloma

10.1056/nejmoa2024850 · 2021 · External reference

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

10.1016/s0140-6736(21)00933-8 · 2021 · External reference

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

10.1016/s1470-2045(19)30788-0 · 2020 · External reference

Teclistamab in relapsed or refractory multiple myeloma

10.1056/nejmoa2203478 · 2022 · External reference

Update on B-cell maturation antigen-directed therapies in AL amyloidosis

10.1111/bjh.19960 · 2025 · External reference

Unresolved reference

External reference

Efficacy and safety of anti-B-cell maturation antigen chimeric antigen receptor T-cell for the treatment of relapsed and refractory AL amyloidosis

10.1200/jco-24-02252 · 2025 · External reference

Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis

10.1111/ejh.14293 · 2024 · External reference

First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma

10.1136/jitc-2021-003783 · 2021 · External reference

First 20-patient safety and efficacy data from NEXICART-2, the first U.S. trial of CAR-T in R/R light chain (AL) amyloidosis, NXC-201

10.1182/blood-2025-696 · 2025 · External reference

The real-world safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy in systemic AL amyloidosis

10.1182/blood-2025-2181 · 2025 · External reference

AL amyloidosis: a real-world experience with CAR T-cell therapy

10.1182/bloodadvances.2025017488 · 2026 · External reference

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis

10.1182/blood.2025028383 · 2025 · External reference

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis

10.1038/s41408-023-00950-3 · 2023 · External reference

First report of teclistamab in a patient with relapsed AL amyloidosis and multiple myeloma

10.1002/jha2.772 · 2023 · External reference

Safety and efficacy of teclistamab in patients with relapsed or refractory AL amyloidosis

10.1111/ejh.14348 · 2025 · External reference

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

10.1182/blood-2025-692 · 2025 · External reference

10.1002/ajh.70140

10.1002/ajh.70140 · 2026 · External reference

High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis

10.1038/s41408-022-00717-2 · 2022 · External reference

Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis

10.1111/bjh.19286 · 2024 · External reference

Belantamab mafodotin in relapsed/refractory AL amyloidosis: real-world multi-center experience and review of the literature

10.1159/000541594 · 2025 · External reference

Efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: a phase 2 study by the European Myeloma Network [abstract]

2023 · External reference

Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma

10.1007/s00277-022-04890-z · 2022 · External reference

Anti-B cell maturation antigen chimeric antigen receptor T cell therapy for the treatment of AL amyloidosis and concurrent relapsed/refractory multiple myeloma: preliminary efficacy and safety

10.3390/curroncol30110697 · 2023 · External reference

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

10.1182/blood.2023022937 · 2024 · External reference

Teclistamab induces rapid responses in patients with relapsed/refractory AL amyloidosis

10.1182/blood-2023-182971 · 2023 · External reference

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

10.1182/blood-2005-07-2922 · 2006 · External reference

Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis

10.1002/ajh.25566 · 2019 · External reference

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

10.1182/blood-2012-12-473066 · 2013 · External reference

Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline

10.1200/jco.21.01992 · 2021 · External reference